secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001576885-23-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports positive Phase 1 results for ACU193; Q2 net loss $11.6M, cash $172.2M + $122M offering
--------------------------------------------------------------------------------

- Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).
- ACU193 demonstrated near-maximal target engagement of toxic AβOs; low ARIA-E rate of 10.4%, symptomatic 2.1%; no drug-related SAEs.
- Cash, equivalents & securities $172.2M at June 30; July follow-on offering added ~$122M net; runway into H2 2026.
- Phase 2 study initiation expected H1 2024; FDA interaction anticipated Q4 2023 to inform development path.
- Q2 2023 net loss $11.6M vs $10.2M YoY; R&D expenses $9.1M (up from $7.3M); no revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/0001576885-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/abos-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001576885-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer